Quince Therapeutics IncNASDAQ:QNCX
- LAST PRICE1.0600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.9900/ 30
- Ask / Lots1.1500/ 2
- Open / Previous Close1.0300 / 1.0600
- Day Range
- 52 Week Range
- Volume57,652
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QNCX |
|---|---|---|
| 09:32 ET | 738 | 1 |
| 09:34 ET | 500 | 1.05 |
| 09:36 ET | 2905 | 1.05 |
| 09:52 ET | 100 | 1.05 |
| 09:54 ET | 100 | 1.05 |
| 10:03 ET | 100 | 1.05 |
| 10:06 ET | 290 | 1.05 |
| 10:46 ET | 100 | 1.05 |
| 10:50 ET | 123 | 1.0501 |
| 10:51 ET | 100 | 1.05 |
| 11:13 ET | 570 | 1.05 |
| 11:36 ET | 800 | 1.05 |
| 11:49 ET | 100 | 1.05 |
| 12:02 ET | 8612 | 1.07 |
| 12:03 ET | 100 | 1.07 |
| 12:05 ET | 500 | 1.0595 |
| 12:38 ET | 400 | 1.05 |
| 12:48 ET | 100 | 1.05 |
| 12:54 ET | 100 | 1.055 |
| 01:14 ET | 1579 | 1.05 |
| 01:24 ET | 650 | 1.05 |
| 01:26 ET | 130 | 1.05 |
| 01:57 ET | 100 | 1.05 |
| 02:08 ET | 155 | 1.0513 |
| 02:20 ET | 400 | 1.05 |
| 02:40 ET | 600 | 1.05 |
| 02:54 ET | 1600 | 1.05 |
| 02:56 ET | 100 | 1.05 |
| 03:02 ET | 100 | 1.05 |
| 03:21 ET | 12820 | 1.05 |
| 03:27 ET | 100 | 1.05 |
| 03:32 ET | 100 | 1.05 |
| 03:36 ET | 100 | 1.05 |
| 03:38 ET | 2540 | 1.075 |
| 03:41 ET | 5280 | 1.05 |
| 03:43 ET | 100 | 1.05 |
| 03:48 ET | 100 | 1.05 |
| 03:50 ET | 440 | 1.05 |
| 03:52 ET | 100 | 1.05 |
| 03:54 ET | 299 | 1.05 |
| 03:56 ET | 5711 | 1.06 |
| 03:57 ET | 310 | 1.06 |
Apr 1, 2024
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results, from 7:00AM ET on Monday Apr 01, 2024 by Dow Jones
7:00AM ET on Monday Apr 01, 2024 by Dow JonesPress Release: Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results, from 7:00AM ET on Monday Apr 01, 2024 by Dow Jones
7:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Quince Therapeutics Inc | 45.4M | -1.3x | --- |
NextCure Inc | 44.6M | -0.7x | --- |
IN8BIO, Inc. | 44.6M | -1.0x | --- |
Eledon Pharmaceuticals Inc | 46.2M | -1.1x | --- |
Maia Biotechnology Inc | 44.3M | -1.5x | --- |
CalciMedica Inc | 43.2M | -0.2x | --- |
Company Information
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. The Company’s asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous intracellular drug encapsulation (AIDE). Its proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patient’s own red blood cells to deliver the sustained therapeutic over a once-monthly treatment period. The Company is also designed to allow for the chronic administration of the therapeutic. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics. The Company also intends to investigate additional potential applications of the AIDE technology platform.
Contact Information
- Headquarters
- 601 Gateway Boulevard, Suite 1250SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 415-910-5717
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Lamond
- President
- Charles Ryan
- Chief Executive Officer, Director
- Dirk Thye
- Chief Financial Officer, Chief Business Officer
- Brendan Hannah
- Lead Independent Director
- Una Ryan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $45.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 43.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-0.84 |
Book Value | $1.98 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
